Anixa Biosciences, Inc. (ANIX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Anixa Biosciences, Inc. (ANIX) is down 18.3% since the beginning of the year. At $3 per share, ANIX is trading 53.3% below its 52-week high of $5. Investors who bought $1,000 worth of ANIX shares 5 years ago would now be looking at an investment worth $649.

Anixa Biosciences, Inc. (ANIX) has returned -18.27% so far this year and -9.57% over the past 12 months. Over the last ten years, ANIX has returned -2.43% per year, falling short of the S&P 500 Index benchmark, which averaged 13.66% annually.

Based on dividend-adjusted daily data since Jan 2, 2001, ANIX's average daily return is +0.19%, while the average monthly return is +2.67%. At this rate, an investment would double in approximately 2.2 years.

Historically, 41% of months were positive and 59% were negative. The best month was Sep 2017 with a return of +292.0%, while the worst month was May 2017 at -56.9%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 10 months.

On a daily basis, ANIX closed higher 42% of trading days. The best single day was Sep 18, 2017 with a return of +85.5%, while the worst single day was May 3, 2017 at -37.5%.

Anixa Biosciences, Inc. has an annualized alpha of 52.25%, beta of 0.57, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since January 03, 2001.

• This stock participated in 159.38% of S&P 500 Index downside but only 107.20% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.57 may look defensive, but with R2 of 0.01 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

ANIX ranks 35 for risk / return — below 35% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The table below present risk-adjusted performance metrics for Anixa Biosciences, Inc. (ANIX) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Anixa Biosciences, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Anixa Biosciences, Inc. was 98.74%, occurring on Aug 15, 2017. The portfolio has not yet recovered.

The current Anixa Biosciences, Inc. drawdown is 94.63%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Anixa Biosciences, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Anixa Biosciences, Inc. is priced in the market compared to other companies in the Diagnostics & Research industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.